Ocugen, Inc.

Ocugen, Inc. has entered into an exclusive license agreement with Celairis Therapeutics Holdings Pty Ltd for its investigational gene therapy, OCU400, in Australia, New Zealand, and ASEAN markets. Under the agreement, Ocugen will receive an upfront license fee, potential development and milestone payments totaling up to $7.1 million, a high-single digit percentage royalty on net sales, and 50% of gross profits. Celairis will be responsible for regional regulatory submissions and commercialization, while Ocugen retains manufacturing rights. This strategic partnership aims to expand patient access to OCU400, a potential one-time treatment for retinitis pigmentosa.

Ocugen, Inc. announced its third quarter 2026 financial results, reporting a net loss of $3.6 million, an improvement from the $20.1 million net loss in the same period last year. The company ended the quarter with $84.6 million in cash and investments, projecting a runway into 2028. Key business updates include the initiation of the Phase 3 ArMaDa3 trial for OCU410, provisional approval for OCU400 in The Bahamas, and an exclusive license agreement for OCU400 in the MENA region. Top-line data for the OCU400 Phase 3 trial is anticipated in Q1 2027.

Ocugen reported a net loss of $24.9 million for Q2 2026, an increase from $14.7 million in Q2 2025. Despite this, the company significantly boosted its cash and cash equivalents to $100.1 million as of June 30, 2026, up from $18.6 million at year-end 2025, primarily due to recent financing activities. These activities included $112.5 million net proceeds from convertible senior notes, which also facilitated the repayment of $32.7 million in long-term debt. However, management expressed substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows.

Ocugen, Inc. reported its second quarter 2026 financial results, including a net loss of $24.9 million. The company announced significant clinical advancements, including FDA clearance to initiate the OCU410 Phase 3 trial for geographic atrophy and the granting of Regenerative Medicine Advanced Therapy (RMAT) designation for OCU410. Financially, Ocugen closed a $130.0 million convertible senior notes financing, extending its cash runway into 2028, and signed a binding term sheet for an exclusive OCU400 license in the MENA region with potential milestones up to $255 million.

Ocugen reported Q2 2026 financial results, alongside significant clinical and corporate advancements. The company received FDA clearance to initiate the OCU410 Phase 3 trial for geographic atrophy and was granted Regenerative Medicine Advanced Therapy (RMAT) designation, enabling priority review. Ocugen also secured $130.0 million in convertible senior notes financing, extending its cash runway into 2028, and signed a binding term sheet for an exclusive OCU400 license in the MENA region. The company reported a net loss of $0.07 per share for the quarter.

Ocugen, Inc. announced it will present its innovative modifier gene therapy platform at two upcoming investor conferences in August 2026. The company will participate in a panel discussion at the Oppenheimer 4th Annual Biotech in the Berkshires Summit on August 4, 2026. Additionally, Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, will deliver a fireside chat at the Canaccord 46th Annual Growth Conference on August 11, 2026, with a webcast available for the latter event.

Ocugen is seeking shareholder approval to amend its charter to increase the number of authorized common shares by 250,000,000, raising the total to 640,000,000. This increase is crucial for future equity financings, strategic transactions, and equity incentive plans, and is also required to allow for the conversion of $130.0 million in convertible senior notes into shares. While the company acknowledges potential dilution for existing shareholders, it emphasizes the importance of this flexibility for long-term growth and to avoid cash settlement of the notes.

Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational product OCU410 for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). This designation, supported by positive Phase 2 clinical data, is expected to expedite the regulatory path for OCU410, which is being developed as a one-time gene therapy. The company has aligned with the FDA on the Phase 3 trial design, with initiation expected in Q3 2026 and a BLA filing anticipated in 2028.

Ocugen, Inc. announced it will host a conference call and live webcast on Thursday, August 6, 2026, at 8:30 a.m. ET. The call will cover the company's second quarter 2026 financial results and provide a business update. A pre-market earnings announcement is also scheduled for the same day.

Ocugen, Inc. announced a binding term sheet with Roots Pharmaceutical and Al-Dhow International Holding to license its OCU400 modifier gene therapy for Retinitis Pigmentosa in the Middle East and North Africa (MENA) region. Under the agreement, Ocugen is set to receive up to $4 million in upfront and near-term development milestones, up to $255 million in sales milestones, and a 22% royalty on net sales. Ocugen will also manufacture and supply OCU400. The definitive agreement is anticipated within 90 days, while OCU400 continues its Phase 3 clinical development with a topline readout expected in Q1 2027.